Pneumococcal Disease EU

CME

Pneumococcal Disease: Current Concepts for At-Risk Adults

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: August 22, 2024

Expiration: August 21, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, Elisabeth Botelho-Nevers, MD, PhD, HDR, discusses current data and trends of pneumococcal disease in Europe, including disease burden on patients and the healthcare system, a spotlight on S. pneumoniae serotypes, and an overview of pneumococcal vaccines, including the different various types and expert-informed recommendations.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Check back for updates as they are available! 

Clinical Care Options plans to measure the educational impact of this activity. The questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

How many people with pneumococcal infections do you provide care for in a typical month?

Your colleague would like to give pneumococcal vaccine to a 56-year-old patient with hypertension and chronic kidney disease. Is this patient at risk for pneumococcal disease and could they benefit from vaccination? 

Which pneumococcal serotypes most commonly cause disease in adults in Europe?

Your colleague wants to know how V116, a pneumococcal vaccine in development, will differ from the recently approved 20-valent conjugate vaccine (PCV20). How do you respond? V116 is a: